SCHEMBL30924756

SCHEMBL30924756

CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 1/20 0.43
▸ GRIN3B O60391 1/20 0.43
▸ GRIN1 Q05586 1/20 0.43
▸ GRIN2A Q12879 1/20 0.43
▸ GRIN2B Q13224 1/20 0.43
▸ GRIN2C Q14957 1/20 0.43
▸ GRIN3A Q8TCU5 1/20 0.43
▸ NMT2 O60551 1/20 0.42
▸ NMT1 P30419 1/20 0.42
▸ BACE1 P56817 4/20 0.41
▸ FURIN P09958 1/20 0.39
▸ PCSK6 P29122 1/20 0.39
▸ KISS1R Q969F8 5/20 0.38
▸ F2 P00734 1/20 0.38
▸ F10 P00742 1/20 0.38
▸ HPN P05981 1/20 0.38
▸ HGFAC Q04756 1/20 0.38
▸ ST14 Q9Y5Y6 1/20 0.38
▸ NPY1R P25929 1/20 0.37
▸ NPY2R P49146 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29473693 0.89 GRIN2D (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30484829 0.85 NPY1R (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29473689 0.85 NPY4R (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30446955 0.83 FOLH1 (0.49) BACE1
SCHEMBL29462923 0.83 NMT2 (0.45) NMT2NMT1BACE1MME
SCHEMBL1711321 0.82 CPB2 (0.47) FURINPCSK6NPY1RNPY2RNPY4R
SCHEMBL30284335 0.82 CPB2 (0.45) NMT2NMT1FURINPCSK6NPY1R
SCHEMBL1711738 0.82 CPB2 (0.47) FURINPCSK6NPY1RNPY2RNPY4R
SCHEMBL1711325 0.82 CPB2 (0.47) FURINPCSK6NPY1RNPY2RNPY4R
SCHEMBL1711732 0.82 CPB2 (0.47) FURINPCSK6NPY1RNPY2RNPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2025-01-23 — — US disclosed
US-12162956-B2 Peptides and methods for reducing skin pigmentation GLO PHARMA, INC. (US) 2024-12-10 — — US disclosed
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION GLO PHARMA, INC. 2024-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190917-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R GRIN2D 4783/4885GRIN3B 3637/4885GRIN1 4399/4885
US-12162956-B2 Peptides and methods for reducing skin pigmentation MC1R, TYR, MC5R GRIN2D 4783/4885GRIN3B 3637/4885GRIN1 4399/4885
US-20250026787-A1 PEPTIDES AND METHODS FOR REDUCING SKIN PIGMENTATION MC1R, TYR, MC5R GRIN2D 4783/4885GRIN3B 3637/4885GRIN1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback